PharmaJet, a company focused on improving injectable delivery through needle-free technology, has signed a Memorandum of Understanding (MoU) with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma, a leading pharmaceutical company in the Middle East and Africa.

The agreement explores introducing needle-free delivery of inactivated polio vaccine (IPV) into Egypt’s routine immunization program. The signing took place at the African Health ExCon healthcare conference in Cairo on June 26.

The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development, and expanding needle-free access in Egypt and across the region.

The UPA aims to bring new technologies into its healthcare portfolio. Its goals include increasing vaccination coverage, improving pandemic preparedness, reducing overall immunization costs, and managing foreign exchange more efficiently. Adopting PharmaJet’s Tropis® Needle-Free system could help Egypt achieve these goals, offering estimated cost savings of 38% or more over six years¹, reducing vaccine hesitancy, increasing coverage, and supporting local medical technology production.

EVA Pharma, with experience in manufacturing, registering, marketing, and promoting pharmaceutical products, will help localize the technology.

“This collaboration can transform immunization by making it safer, more accessible, and less painful for children and caregivers,” said Nicolas Boege, Director of Global Commercial & Corporate Development at EVA Pharma. “By introducing this technology and localizing its manufacturing, we are committed to scaling innovation that strengthens public health systems. We are proud to work with UPA and PharmaJet to bring needle-free delivery to Egypt’s immunization programs and beyond.”

The introduction of Tropis, along with local manufacturing, supports the UPA’s goal of becoming a leader in immunization and a hub for needle-free product manufacturing in the Middle East and North Africa. The initiative will also contribute to pandemic preparedness, reduce immunization costs, and support Egypt’s Universal Health Insurance project. It aligns with the country’s focus on early childhood health, building on the ‘1000 Golden Days’ presidential initiative.

“This collaboration with UPA and EVA Pharma can bring the benefits of intradermal (ID) delivery—reduced pain and faster administration—to children in Egypt,” said Paul LaBarre, Vice President of Business Development at PharmaJet. “The UPA will gain from cost savings and new opportunities in pharmaceutical product development and manufacturing. We’re excited to expand PharmaJet’s reach into Egypt and the region. We look forward to helping improve early childhood development through needle-free immunization.”